EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Predictive value of natural killer (NK) cells in bone marrow for relapse in diffuse large B cell lymphoma: integrating antibody-dependent cell-mediated cytotoxicity (ADCC)-based immunotherapy

Sofía Rincón-López iD, Johelys Atencio-Matos iD, Olalla Pereda-Sainz iD, Javier Larreina-Pérez iD, Andrea Campeny-Najara, Ada Esteban-Figuerola iD, Montserrat Hernandez-Perez, Puy Garrastachu-Zumaran iD, María Velasco-Ruiz, Isabel García-Bosque iD, Carmen Rodriguez-Lefler iD, Estefanía Ruiz de Gaona und 4 weitere

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04322-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Sofía Rincón-López und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hospital Universitario San Pedro, 26006, Logroño, La Rioja, Spain. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Killer Cells, Natural, Antibody-Dependent Cell Cytotoxicity, Immunotherapy. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Diffuse large B cell lymphoma (DLBCL) is characterized by high relapse rates and immunobiological complexity. The therapeutic efficacy of CD20-targeting monoclonal antibodies depends largely on antibody-dependent cellular cytotoxicity (ADCC), mediated by natural killer (NK) cells. METHODS: We evaluated the percentage of bone marrow NK cells in 47 newly diagnosed DLBCL patients by flow cytometry prior to first-line chemoimmunotherapy. ADCC potential was assessed using immunological parameters. RESULTS: Patients with ≥ 14% bone marrow NK cells had significantly better event-free survival (EFS), with median EFS nearly doubled compared with those below this threshold (HR = 0.24, p 14%. In multivariable Cox regression, bone marrow NK percentage remained independently predictive of EFS after adjustment for International Prognostic Index (IPI), age, and treatment regimen. Although overall survival did not differ significantly, higher NK levels were associated with improved clinical response. CONCLUSION: Patients with higher NK cell percentages may better tolerate chemotherapy-induced depletion, thereby preserving or restoring their effector pool more efficiently. Elevated bone marrow NK cell percentages predict favorable outcomes in DLBCL and support their potential role as translational biomarkers. Incorporating NK cell monitoring into clinical protocols could improve risk stratification and guide immunotherapeutic strategies for personalized patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseKiller Cells, NaturalAntibody-Dependent Cell CytotoxicityImmunotherapyBone MarrowNeoplasm Recurrence, LocalHumansFemaleMaleMiddle AgedAgedAdultPrognosisAged, 80 and overAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Aggressive lymphomaAntibody-dependent cellular cytotoxicity (ADCC)BiomarkerBone marrowDiffuse large B cell lymphoma (DLBCL)Natural killer (NK)

Autor:innen und Institutionen

  • Department of Hematology, Hospital Universitario San Pedro, 26006, Logroño, La Rioja, Spain.
  • Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain.
  • Hematology and Hemotherapy Service, Fundación Hospital Calahorra, Calahorra, La Rioja, Spain.
  • Cell Proliferation and Differentiation Group Oncology Area, CIBIR (Center for Biomedical Research of La Rioja) La Rioja, Logroño, Spain.
  • Medical Oncology Department, Hospital Universitario San Pedro, Logroño, Spain.
  • Department of Hematology, Hospital Universitario San Pedro, 26006, Logroño, La Rioja, Spain. rgmunoz@riojasalud.es.

ORCID-Profile: Sofía Rincón-López, Johelys Atencio-Matos, Olalla Pereda-Sainz, Javier Larreina-Pérez, Ada Esteban-Figuerola, Puy Garrastachu-Zumaran, Isabel García-Bosque, Carmen Rodriguez-Lefler, Jesús Feliu, Juan Cabello, Alfonso Martín-Carnicero, Ricardo García-Muñoz

Zitieren

APA

Rincón-López, S., Atencio-Matos, J., Pereda-Sainz, O., Larreina-Pérez, J., Campeny-Najara, A., Esteban-Figuerola, A., Hernandez-Perez, M., Garrastachu-Zumaran, P., Velasco-Ruiz, M., García-Bosque, I., Rodriguez-Lefler, C., Ruiz de Gaona, E., Feliu, J., Cabello, J., Martín-Carnicero, A., & García-Muñoz, R. (2026). Predictive value of natural killer (NK) cells in bone marrow for relapse in diffuse large B cell lymphoma: integrating antibody-dependent cell-mediated cytotoxicity (ADCC)-based immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04322-1

Vancouver

Rincón-López S, Atencio-Matos J, Pereda-Sainz O, Larreina-Pérez J, Campeny-Najara A, Esteban-Figuerola A, et al. Predictive value of natural killer (NK) cells in bone marrow for relapse in diffuse large B cell lymphoma: integrating antibody-dependent cell-mediated cytotoxicity (ADCC)-based immunotherapy. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04322-1

BibTeX
@article{RincnLpez2026,
  author = {Rincón-López, Sofía and Atencio-Matos, Johelys and Pereda-Sainz, Olalla and Larreina-Pérez, Javier and Campeny-Najara, Andrea and Esteban-Figuerola, Ada and Hernandez-Perez, Montserrat and Garrastachu-Zumaran, Puy and Velasco-Ruiz, María and García-Bosque, Isabel and Rodriguez-Lefler, Carmen and Ruiz de Gaona, Estefanía and Feliu, Jesús and Cabello, Juan and Martín-Carnicero, Alfonso and García-Muñoz, Ricardo},
  title = {Predictive value of natural killer (NK) cells in bone marrow for relapse in diffuse large B cell lymphoma: integrating antibody-dependent cell-mediated cytotoxicity (ADCC)-based immunotherapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04322-1}
}
Kostenlos starten →